Clinical Report: Prime Editing Corrects GATA2 Deficiency in Patient Stem Cells

Overview

In a preclinical study, prime editing repaired a disease-causing GATA2 deletion in patient-derived CD34-positive hematopoietic stem and progenitor cells. Editing exceeded 70% after optimization, increased functional GATA2 alleles from 50% to as much as 77%, and was associated with improved engraftment in immunodeficient mice; the findings do not establish clinical efficacy in patients.

Background

GATA2 deficiency is an inherited disorder caused by mutations affecting one copy of the GATA2 gene, which contributes to blood stem cell maintenance and immune cell production. The condition can involve severe infections, bone marrow failure, and increased risk of myeloid cancers. Allogeneic hematopoietic stem cell transplantation is described in the source as the only curative treatment, but it carries risks including graft-versus-host disease and graft failure. GATA2 deficiency is also included among inborn errors of immunity, and contemporary practice parameters cited in the web research context describe myeloid disease as a common complication in hematopoietic IEIs, including GATA2-related disease.

Data Highlights

Key Findings

• The Aarhus University team used prime editing to repair a seven-base-pair deletion in patient-derived CD34-positive hematopoietic stem and progenitor cells.
• Prime editing uses a modified Cas9 protein and reverse transcriptase to rewrite a targeted DNA sequence without the double-strand DNA breaks used in conventional CRISPR editing.
• After optimization, editing exceeded 70% in CD34-positive cells, with limited reported effects on cell fitness; functional GATA2 alleles rose from 50% to as much as 77%, alongside increased GATA2 protein expression.
• Edited cells retained blood-cell colony-forming capacity and achieved up to 2.73-fold greater engraftment than untreated cells in immunodeficient mice; editing persisted in repopulating stem cells at 16 weeks.
• Researchers reported limited unintended changes at the target site and no editing at the 20 highest-ranked predicted off-target sites. Reducing stem-cell stimulation to less than 24 hours before editing reduced the DNA damage response and improved multilineage engraftment.
• PASSIGE was used to insert a larger corrective GATA2 sequence, but integration reached 4.6% of alleles. A related GATA2 study in Blood Cancer Journal addresses allele-specific expression and hematopoietic stem-cell hyporesponsiveness, while the supplied web context notes ongoing surveillance for myeloid disease in GATA2-related IEIs.

Clinical Implications

These results support further investigation of autologous prime editing as a potential approach to correcting GATA2 deficiency, but the evidence presented is preclinical and includes transplantation experiments in mice. The supplied practice-parameter context describes ongoing blood-count and bone-marrow surveillance for myeloid disease in IEIs with hematopoietic defects, including GATA2; the study does not establish that gene editing can replace current clinical management or transplantation.

Conclusion

Prime editing corrected a GATA2 mutation in patient-derived stem and progenitor cells and improved engraftment in a mouse model, with editing maintained in repopulating cells for 16 weeks. Larger-sequence integration remained low, and clinical efficacy and safety in patients are not established by the reported preclinical findings.

Related Resources & Content

1. Blood Cancer Journal, 2025 -- Association of GATA2 Allele-Specific Expression with Hyporesponsiveness in Hematopoietic Stem Cells in GATA2 Deficiency Syndrome
2. International Union of Immunological Societies Expert Committee, 2024 -- Human inborn errors of immunity: 2024 update on the classification
3. EBMT, 2025 -- EBMT Releases 2025 Practice Recommendations for HCT and CAR-T Therapy
4. Ophthalmology Management — Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
5. the medicine maker — CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
6. the medicine maker — The Sickle Cell Solution
7. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee
8. EBMT Releases 2025 Practice Recommendations for HCT and CAR-T Therapy
9. Prime Editing for p47phox-Deficient Chronic Granulomatous Disease - PubMed